Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use.
By P. Kurtzhals, L. Schäffer, A. Sorensen, C. Kristensen, I. Jonassen, C. Schmid, T. Trüb. Diabetes, 2000
768 citations recorded by the source corpus.
Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology, Surgery
View Paper: https://www.semanticscholar.org/paper/afed12c094c9ee17ad783d9b99a54612d7b59309
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
In Molecular Biology
In Surgery
Citations in the corpus
- The insulin and insulin-like growth factor receptor family in neoplasia: an update (2012, background): “It is plausible that synthetic insulins could interact differently from endogenous insulins with IIRF members that are present on tissues owing to variations in receptor-binding specificity (for example, increased affinity for IGF1R or hybrid receptors, or stronger binding to insulin receptors), or ”
- Insulin and its analogs: actions via insulin and IGF receptors (2010, methodology): “Among short-acting analogs, two out of three studies indicate that Lispro has a slightly higher affinity for the IGF-IR in comparison to insulin (Table 3) [11], while in one study, Aspart insulin was found to bind IGF-IR less than insulin [11].”
- Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. (2009, background): “Studies on commercially available insulin analogs are limited (258, 262, 263).”
- Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study (2009, background): “Comparison of the mitogenic potency of insulin analogues relative to human insulin in cell experiments showed that B10Asp was tenfold and glargine (A21Gly,B31Arg,B32Arg human insulin) was eightfold more potent, whereas lispro (B28Lys,B29Pro human insulin) and aspart (B28Asp human insulin) were sligh”
- The influence of glucose-lowering therapies on cancer risk in type 2 diabetes (2009, background): “Laboratory studies have demonstrated that insulin levels (often, but not always, supraphysiological) may have direct effects in vitro on growth, proliferation and resistance to apoptosis of cancer cells [7, 8].”